Related Experiment Video
Updated: May 13, 2026
07:05
Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
Published on: November 9, 2016
Botulinum toxin for meralgia paresthetica in type 2 diabetes
Pawan Dhull1, A K Tewari, Vimal Upreti
1Department of Neurology, Command Hospital, Bangalore, India.
Diabetes & Metabolic Syndrome
|March 23, 2013
Summary
Botulinum toxin may offer a new treatment for meralgia paresthetica, a painful nerve condition often seen in type 2 diabetes. This study explored its effectiveness in patients with diabetes mellitus who did not respond to other therapies.
Area of Science:
- Neurology
- Endocrinology
- Diabetology
Background:
- Meralgia paresthetica is a common mononeuropathy affecting the femoral nerve.
- It is frequently associated with diabetes mellitus and obesity.
- The exact cause of meralgia paresthetica is not fully understood.
Purpose of the Study:
- To investigate the efficacy of botulinum toxin in treating meralgia paresthetica.
- To evaluate botulinum toxin as a therapeutic option for resistant cases.
- To explore the role of botulinum toxin in type 2 diabetes-related neuropathic conditions.
Main Methods:
- A study was conducted on patients with meralgia paresthetica.
- The study focused on individuals with type 2 diabetes.
- Botulinum toxin was administered to participants with treatment-resistant symptoms.
Main Results:
- The study assessed the outcomes of botulinum toxin treatment.
- Results indicated the potential of botulinum toxin for specific neuropathic conditions.
- Effectiveness in resistant meralgia paresthetica cases was examined.
Conclusions:
- Botulinum toxin shows promise as a treatment for meralgia paresthetica.
- Further research is warranted to confirm its role in managing diabetic neuropathy.
- This approach may benefit patients with type 2 diabetes and resistant symptoms.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
01:31Skeletal Muscle Relaxants: Therapeutic Uses
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
01:28Classification of Skeletal Muscle Relaxants
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:22Diabetic Neuropathy
DefinitionDiabetic neuropathy is nerve damage caused by long-standing diabetes mellitus. It results directly from prolonged high blood sugar levels.PathophysiologyThe pathophysiology of diabetic neuropathy involves both metabolic and vascular disturbances triggered by chronic hyperglycemia.Metabolic injury: Elevated glucose levels activate the polyol pathway within nerve cells, leading to the accumulation of sorbitol and fructose. This increases oxidative stress, disrupts normal nerve...
01:27Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Although all competitive neuromuscular blockers are designed...